Myxomatous Mitral Valve Disease in Dogs

Professional summary: An ACVIM-stage-based reference on canine myxomatous mitral valve disease, from incidental murmur to congestive heart failure.

Clinical overview

Myxomatous mitral valve disease is the most common acquired cardiac disease in dogs, particularly older small breeds. Degeneration causes mitral regurgitation, progressive chamber enlargement and, in some dogs, congestive heart failure.

Use the reference as a structured starting point. The patient's species, age, breed, physiologic state, disease duration and previous treatment can substantially change the diagnostic and management pathway. Where the presentation is atypical, return to first principles and reconsider the problem list before adding therapy.

Clinical presentation

Early disease is often identified through an apical systolic murmur in an otherwise well dog. Progression may cause increased sleeping respiratory rate, exercise intolerance, cough, tachypnoea, dyspnoea, weakness or syncope. Cough should not automatically be attributed to heart failure because airway disease is common in the same population.

Severity should be judged from function and trend rather than from one isolated sign. Record onset, progression, triggers, appetite, drinking, elimination, activity and sleep. Videos or home observations can reveal abnormalities that are absent in the consulting room, particularly for intermittent lameness, coughing, pain and behavioural change.

Diagnostic approach

Thoracic radiographs assess cardiac silhouette, pulmonary vessels and pulmonary oedema. Echocardiography confirms valve morphology and quantifies chamber enlargement and haemodynamic effects. Blood pressure, electrocardiography and selected biomarkers can provide additional information. ACVIM staging separates at-risk dogs, preclinical disease without or with enlargement, current heart failure and refractory disease.

Choose tests that answer a defined clinical question. Confirm sample quality and interpret results against hydration, stress, recent medication and pre-test probability. Repeating a focused examination or measurement after stabilisation is often more informative than ordering a broad panel without a plan for how the result will alter management.

Treatment and management

Stage-specific management is essential. Dogs without relevant enlargement are generally monitored. Evidence supports pimobendan in appropriately defined preclinical dogs with cardiomegaly. Heart failure treatment commonly includes diuresis and other cardiac medication tailored to the patient. Oxygen, stress reduction and urgent stabilisation are priorities in respiratory distress.

Set immediate and longer-term goals, then reassess whether each intervention is achieving them. Minimise unnecessary polypharmacy and document the reason for every medicine, procedure and restriction. Where treatment carries important renal, hepatic, gastrointestinal, cardiovascular or behavioural risk, establish a monitoring plan before discharge.

Monitoring and reassessment

Owners should be taught to measure sleeping respiratory rate and recognise increased effort. Rechecks assess symptoms, renal values, electrolytes, blood pressure, radiographs and echocardiographic progression as appropriate.

Define what improvement should look like and when it should occur. A useful monitoring plan names the variable, method, frequency and threshold for action. Failure to improve within the expected window, recurrence after initial response or emergence of new systemic signs should trigger diagnostic review rather than automatic repetition of the same treatment.

Prognosis

Many dogs remain preclinical for years. Once heart failure develops, prognosis varies with response, renal tolerance, arrhythmia, pulmonary hypertension and owner monitoring.

Prognosis should be presented as a range and updated as response becomes clear. Separate survival, functional recovery, recurrence risk, long-term medication burden and quality of life. Discuss factors that can be modified, such as body condition, adherence and timely rechecks, alongside factors that cannot.

Clinical priorities

Begin with patient stability, pain and welfare. Urgent respiratory compromise, circulatory shock, severe neurological deterioration, inability to urinate, uncontrolled haemorrhage or rapidly progressive abdominal disease should be addressed before a complete elective work-up. The order of investigation should be adapted to the patient's tolerance and the likelihood that a delay will change outcome.

Differential diagnoses and concurrent disease

Avoid anchoring on the first plausible diagnosis. Build a prioritised differential list from signalment, time course, examination and objective tests. Concurrent disease can alter both clinical signs and treatment tolerance. Medication history, nutrition, reproductive status, travel, environment and previous response to therapy should be reviewed because each may expose an alternative explanation or a factor that needs treatment in parallel.

Communication with the owner or carer

Explain the working diagnosis, degree of certainty, immediate priorities and expected decision points. Provide clear instructions on medication administration, activity, feeding, monitoring and emergency warning signs. Where several treatment pathways are reasonable, discuss expected benefits, limitations, cost, follow-up burden and the consequences of delayed escalation. Written plans reduce misunderstanding and support continuity between clinicians.

Prevention and long-term care

Prevention depends on the underlying disorder and may include body-condition management, appropriate exercise, environmental modification, preventive healthcare, early screening and prompt review of recurrent signs. Long-term plans should be practical for the household or yard and reviewed when circumstances change. A technically ideal plan that cannot be followed consistently is less useful than a safe, prioritised plan with measurable goals.

Evidence and clinical judgement

Published guidelines and consensus statements provide a framework but do not replace examination of the individual patient. Recommendations may differ between countries because of drug licensing, antimicrobial policy, available diagnostics and referral access. Use current product information, local regulations and specialist advice where needed. This reference deliberately avoids fixed drug doses because dosing depends on species, weight, formulation, route, organ function and the complete clinical context.

Key clinical points

• Stabilise urgent threats before completing the full diagnostic pathway.
• Use history, examination and objective findings together; avoid relying on one test.
• Select treatment according to severity, patient factors and the underlying cause.
• Reassess response using defined clinical and laboratory goals.
• Escalate promptly when deterioration, treatment intolerance or an unexpected course develops.

Frequently asked clinical questions

When should myxomatous mitral valve disease in dogs be treated as urgent?

Urgency is determined by physiologic stability, speed of progression, pain, loss of normal function and the risk of irreversible injury. Respiratory distress, collapse, shock, severe or escalating pain, inability to pass urine, rapidly worsening neurological deficits, repeated unproductive retching, marked abdominal distension or a sudden change in mentation require immediate assessment. A patient can have a serious disorder before routine laboratory values become markedly abnormal, so triage should begin with the patient rather than the test result.

What is the most common reason for an incomplete response?

Common reasons include an incorrect or incomplete diagnosis, an untreated concurrent disorder, insufficient duration, poor administration technique, unrealistic activity or feeding instructions, and failure to reassess after the first intervention. In chronic disease, control may fluctuate even when the original diagnosis is correct. Review adherence respectfully, confirm that the owner can carry out the plan, and repeat focused examination or testing before simply escalating medication.

How should follow-up be planned?

Follow-up should be matched to the expected pace of change and treatment risk. Unstable or recently discharged patients may need reassessment within hours or days, whereas stable chronic disease may be reviewed at longer intervals. Give owners measurable home observations such as respiratory rate, appetite, water intake, urine output, body weight, pain score, mobility or episode frequency. State exactly which change should trigger earlier contact.

Can a standard protocol be used for every patient?

No. Protocols improve consistency, but they must be adapted for species, size, age, pregnancy, temperament, organ function, concurrent medicines, referral availability and owner circumstances. Treatment that is licensed or routine in one country may not be appropriate in another. Record the clinical reasoning behind departures from a protocol and use the least complex plan that safely meets the patient’s needs.

References and further reading

1. ACVIM Consensus Guidelines for the Diagnosis and Treatment of Myxomatous Mitral Valve Disease in Dogs.
2. Merck Veterinary Manual. Mitral Valve Disease in Dogs.
3. European Society of Veterinary Cardiology educational resources.

Last editorial preparation: August 2026. Verify current guidelines, medicines and local regulations before clinical use.